NCT07163364View on ClinicalTrials.gov

A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 8, 2026

Study Completion Date

April 28, 2027

Conditions

Methylmalonic Acidemia (MMA)

Interventions

DRUG

Hydroxocobalamin Chloride Injection

1 - 20 mg per dose, 1 - 5 times per week

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY